文献速递中医内科中药与中成药合理使用

金银花辅助治疗新型冠状病毒肺炎的系统评价与Meta分析

Add-On Effect of Honeysuckle in the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2021-09-15

该系统评价与Meta分析纳入9项RCT共1286例成人COVID-19患者,评价金银花联合常规治疗的疗效与安全性。结果显示联合治疗在肺部CT改善、临床治愈率和转重率方面优于常规治疗,并可改善发热和咳嗽症状及炎症指标,未增加不良事件。

要点

  • 金银花联合常规治疗可改善COVID-19患者肺部CT表现(RR=1.24)。
  • 联合治疗提高临床治愈率(RR=1.21)并降低转重率(RR=0.50)。
  • 联合治疗未增加不良药物事件,但需更多高质量RCT验证。

核心结论

  • 金银花联合常规治疗可能有利于改善COVID-19患者的肺部CT、临床治愈率、临床症状和实验室指标,并降低转重率。
  • 联合治疗未增加不良药物事件。
  • 未来需要更多高质量RCT进一步验证。

研究设计与样本

  • 系统评价与Meta分析,检索7个电子数据库(PubMed、EMBASE、Cochrane Library、CNKI、维普、万方、CBM)的RCT。
  • 纳入9项RCT,共1286例成人(年龄≥18岁)COVID-19患者。
  • 采用Cochrane偏倚风险工具评估方法学质量,Review Manager 5.3软件进行数据分析。

主要发现

  • 金银花联合常规治疗在肺部CT改善方面优于单纯常规治疗(RR=1.24,95%CI 1.12–1.37,P<0.0001)。
  • 联合治疗提高临床治愈率(RR=1.21,95%CI 1.12–1.31,P<0.00001)。
  • 联合治疗降低转重率(RR=0.50,95%CI 0.33–0.76,P=0.001)。
  • 联合治疗改善发热症状评分、咳嗽减少率、咳嗽症状评分及炎症生物标志物(WBC计数、CRP)(P<0.05)。
  • 联合治疗未增加不良药物事件。

关键数值与推荐

  • 肺部CT改善:RR=1.24,95%CI(1.12,1.37),P<0.0001。
  • 临床治愈率:RR=1.21,95%CI(1.12,1.31),P<0.00001。
  • 转重率:RR=0.50,95%CI(0.33,0.76),P=0.001。

临床怎么用

  • 在常规治疗基础上加用金银花可能改善COVID-19成人患者的肺部CT和临床治愈率。
  • 联合金银花可能降低转重风险,并可改善发热、咳嗽症状及WBC、CRP等炎症指标。
  • 联合治疗未增加不良事件,但临床应用仍需结合患者具体情况。

局限性

  • 纳入研究均为RCT但数量有限(9项),方法学质量需评估。
  • 原文未报告具体偏倚风险评价结果。
  • 未来需要更多高质量RCT进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread to become a global emergency since December 2019. Chinese herbal medicine plays an important role in the treatment of COVID-19. Chinese herbal medicine honeysuckle is an extremely used traditional edible and medicinal herb. Many trials suggest that honeysuckle has obtained a good curative effect for COVID-19; however, no systematic evaluation on the clinical efficacy of honeysuckle in the treatment of COVID-19 is reported. This study aimed to evaluate the efficacy and safety of Chinese herbal medicine honeysuckle in the treatment of COVID-19. Methods: Seven electronic databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and China Biology Medicine) were searched to identify randomized controlled trials (RCTs) of honeysuckle for adult patients (aged ≥ 18 years) with COVID-19. The Cochrane Risk of Bias Tool was applied to assess the methodological quality of trials. Review Manager 5.3 software was used for data analysis. Results: Overall, nine RCTs involving 1,286 patients were enrolled. Our meta-analyses found that combination therapy of honeysuckle and conventional therapy was more effective than conventional therapy alone in lung computed tomography (CT) [relative risk (RR) = 1.24, 95% confidence interval (95%CI) (1.12, 1.37), P < 0.0001], clinical cure rate [RR = 1.21, 95%CI (1.12, 1.31), P < 0.00001], and rate of conversion to severe cases [RR = 0.50, 95%CI (0.33, 0.76), P = 0.001]. Besides, combination therapy can improve the symptom score of fever, cough reduction rate, symptom score of cough, and inflammatory biomarkers (white blood cell (WBC) count; C-reactive protein (CRP)) (P < 0.05). Conclusion: Honeysuckle combined with conventional therapy may be beneficial for the treatment of COVID-19 in improving lung CT, clinical cure rate, clinical symptoms, and laboratory indicators and reducing the rate of conversion to severe cases. Besides, combination therapy did not increase adverse drug events. More high-quality RCTs are needed in the future.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Du XQ, Shi LP, Cao WF, et al. Add-On Effect of Honeysuckle in the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021. PMID: 34603023. doi:10.3389/fphar.2021.708636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。